IL2 and melanoma: Additionally, a 50% overall response rate was observed in cyclophosphamide lymphodepleted stage IV melanoma patients receiving autologous MART-1 (melanoma-associated antigen recognized by T-cells), peptide-pulsed DCs, and ex vivo reactivated tumor-infiltrating lymphocytes plus IL-2 treatment [71].